drugset / Trial / NCT00600990

Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients

NCT00600990

Phase 2 Completed 624 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to determine the effectiveness of this medication in preventing nausea and vomiting in female patients at risk for post-operative nausea and vomiting (PONV).

Timeline

Start
2004-12
Primary completion
2006-07
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Vestipitant Small molecule 3 mg Oral
Subject Vestipitant Small molecule 18 mg Oral
Subject Vestipitant Small molecule 25 mg Oral

Indications

No indication recorded.